Polylactic acid implants. A new smile for lipoatrophic faces?

被引：14

作者：

Boix, V

机构：

[1] Hosp Gen Univ Alicante, Unidad Enfermedades Infecciosas, Alicante, Spain

[2] Hosp Gen Univ Alicante, Infect Dis Unit, Alicante, Spain

来源：

AIDS | 2003年 / 17卷 / 17期

关键词：

facial implants; polylactic acid; lipodystrophy; HIV;

D O I：

10.1097/00002030-200311210-00018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2533 / 2535

页数：3

共 22 条

[1] HIV-associated lipodystrophy syndrome: Description and pathogenesis [J].

Bodasing, N ;

Fox, R .

JOURNAL OF INFECTION, 2003, 46 (03) :149-154

[2] Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy [J].

Calmy, A ;

Hirschel, B ;

Hans, D ;

Karsegard, VL ;

Meier, CA .

AIDS, 2003, 17 (05) :770-772

[3] Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial [J].

Carr, A ;

Workman, C ;

Smith, DE ;

Hoy, J ;

Hudson, J ;

Doong, N ;

Martin, A ;

Amin, J ;

Freund, J ;

Law, M ;

Cooper, DA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :207-215

[4] An objective case definition of lipodystrophy in HIV-infected adults: a case-control study [J].

Carr, A ;

Emery, S ;

Law, I ;

Puls, R ;

Lundgren, JD ;

Powderly, WG ;

Carr, B ;

Cooper, DA ;

Grinspoon, S ;

Ioannidis, J ;

Lewis, R ;

Law, M ;

Lichtenstein, K ;

Murray, J ;

Pizzuti, D ;

Rozenbaum, W ;

Schambelan, M ;

Moore, A ;

Miller, J .

LANCET, 2003, 361 (9359) :726-735

[5]

DELPINO V, 2001, ANTIVIR THER S, V6, P38

[6] Failure to maintain long-term adherence to highly active antiretroviral therapy:: the role of lipodystrophy [J].

Duran, S ;

Savès, M ;

Spire, B ;

Cailleton, V ;

Sobel, A ;

Carrieri, P ;

Salmon, D ;

Moatti, JP ;

Leport, C .

AIDS, 2001, 15 (18) :2441-2444

[7] Incidence of clinical lipodystrophy in HIV-1-infected patients treated during primary infection [J].

Goujard, C ;

Boufassa, F ;

Deveau, C ;

Laskri, D ;

Meyer, L .

AIDS, 2001, 15 (02) :282-284

[8] Metformin in the treatment of HIV lipodystrophy syndrome - A randomized controlled trial [J].

Hadigan, C ;

Corcoran, C ;

Basgoz, N ;

Davis, B ;

Sax, P ;

Grinspoon, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (04) :472-477

[9] Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy [J].

Hatano, H ;

Miller, KD ;

Yoder, CP ;

Yanovski, JA ;

Sebring, NG ;

Jones, EC ;

Davey, RT .

AIDS, 2000, 14 (13) :1935-1942

[10] Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial [J].

Joly, V ;

Flandre, P ;

Meiffredy, V ;

Leturque, N ;

Harel, M ;

Aboulker, JP ;

Yeni, P .

AIDS, 2002, 16 (18) :2447-2454

← 1 2 3 →